Загрузка...
Inebilizumab: First Approval
Inebilizumab (Uplizna™; inebilizumab-cdon in the USA) is a humanised anti-CD19 monoclonal antibody being developed by Viela Bio for the treatment of a range of autoimmune diseases associated with CD19-expressing B cells. Inebilizumab targets and depletes CD19-expressing B cells through antibody-depe...
Сохранить в:
| Опубликовано в: : | Drugs |
|---|---|
| Главный автор: | |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer International Publishing
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7387876/ https://ncbi.nlm.nih.gov/pubmed/32729016 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-020-01370-4 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|